ArticleArchives of toxicology2026
Exposure to per- and polyfluoroalkyl substances (PFAS) and development of autoimmunity in humans and animals: a scoping review.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PFAS are a group of persistent organic pollutants, that bioaccumulate and are associated with negative health effects. Reviews have suggested that the most critical effects of PFAS are on the immune system, but little is known of effects on development of autoimmunity. Our objective was to map and summarize available evidence concerning exposure to any PFAS and development/presence of autoimmunity, in humans and animals. We assessed studies reporting potential associations between PFAS exposure and autoimmune disease and/or autoantibodies. We searched MEDLINE, Embase, CENTRAL, Scopus, and Web of Science (02.15.2024) and conducted complimentary searches. Results were presented descriptively and we categorized autoimmune diseases and autoantibodies into relevant outcome groups. 51 studies were included, distributed in the following groups: Autoimmune thyroid disease, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, celiac disease, other diseases and autoantibodies. Cross-sectional studies were most common, limiting opportunities for causal inference. 33 studies showed associations between higher PFAS and increased risk of autoimmunity, while nine studies found lower PFAS associated with increased autoimmunity risk. The results suggest that PFAS have negative health impacts with strongest evidence for celiac and inflammatory bowel disease, weaker evidence for rheumatoid arthritis, systemic lupus erythematosus and type 1 diabetes mellitus. No clear indications of association with autoimmune thyroid disease. The majority of the studies showed an association between PFAS and autoimmunity. There is a need for more longitudinal and dose-response studies, to improve our understanding of individual autoimmunity outcomes in the future.Protocol registration: OSF.io ( https://doi.org/10.17605/OSF.IO/3FEVQ ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.